Chemotherapy-induced anemia in adults: Incidence and treatment

Journal of the National Cancer Institute

Volumn 91, Issue 19, 1999, Pages 1616-1634

  Groopman, Jerome E ^a   Itri, Loretta M ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; PACLITAXEL; TOPOTECAN; VINBLASTINE;

ANEMIA; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DISEASE SEVERITY; DRUG INDUCED DISEASE; ERYTHROCYTE TRANSFUSION; HEAD AND NECK CANCER; HUMAN; INCIDENCE; LUNG CANCER; LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0033530262     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.19.1616     Document Type: Review

References (161)

1. Glaspy J. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Semin Hematol 1997;34(suppl 2):20-6.
2. Consensus conference. Perioperative red blood cell transfusion. JAMA 1988;260:2700-3.
3. Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992;116:393-402.
4. Surgenor DM, Wallace EL, Hale SG, Gilpatrick MW. Changing patterns of blood transfusions in four sets of United States hospitals, 1980 to 1985. Transfusion 1988;28:513-8.
5. Silberstein LE, Kruskall MS, Stehling LC, Johnston MF, Rutman RC, Samia CT, et al. Strategies for the review of transfusion practices [published erratum appears in JAMA 1990;263:2302]. JAMA 1989;262: 1993-7.
6. Cella D, Mo F, Peterman A. Anemia, fatigue and quality of life in people with cancer and HIV infection [abstract]. Blood 1996;88(suppl 1):146a.
7. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, VadhanRaj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-34.
8. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-25.
9. Ferrell BR, Grant M, Dean GE, Funk B, Ly J. "Bone tired": the experience of fatigue and its impact on quality of life. Oncol Nurs Forum 1996;23:1539-47.
10. Groopman JE. Fatigue in cancer and HIV/AIDS. Oncology (Huntingt) 1998;12:335-14.
11. Irvine D, Vincent L, Graydon JE, Bubela N, Thompson L. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nurs 1994;17:367-78.
12. Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997(suppl 2);34:4-12.
13. Winningham ML, Nail LM, Burke MB, Brophy L, Cimprich B, Joned LS, et al. Fatigue and the cancer experience: the state of the knowledge. Oncol Nurs Forum 1994;21:23-36.
14. Yellen SB, Cella DF, Webster K, Blendowski C. Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63-74.
15. Cella D. The Functional Assessment of Cancer Therapy - Anemia (FACT - An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(suppl 2):13-9.
16. Langer C, Barsevick A, Bruner D, Grindel C, Leighton J, Luckscheiter C, et al. Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel [abstract]. Lung Cancer 1997;18:23.
17. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25(suppl 7):2-6.
18. Dalton JD, Bailey NP, Barrett-Lee PJ, O'Brien MER. Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy [abstract]. Proc ASCO 1998;17:418a.
19. Heddens DK, Alberts DS, Garcia DJ, Hannigan EV, Rothenberg ML. Factors associated with platinum-induced anemia in ovarian cancer (OVCA) patients (pts) in Southwest Oncology Group (S) studies [abstract]. Proc ASCO 1998;17:359a.
20. Skillings JR, Sridhar FG, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 1993;16:22-5.
21. th ed. Philadelphia (PA): Lippincott-Raven; 1997.
22. Greco FA, ed. Handbook of commonly used chemotherapy regimens. Chicago (IL): Precept Press; 1996.
23. Anon. Drugs of choice for cancer chemotherapy. Med Lett Drugs Ther 1997;39:21-8.
24. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997, by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
25. Carlson RW, McCormick B, Goldstein LJ, Moe RE, Gradishar WJ, Theriault RL, et al. Update of the NCCN guidelines for treatment of breast cancer. Oncology 1997:11(11A):199-220.
26. Carlson RW, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Moe RE, et al. NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10(11 suppl):47-75.
27. Demetri G, Elias A, Gershenson D, Fossella F, Grecula J, Mittal B, et al. NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10(11 suppl): 179-94.
28. Engstrom PF, Benson AB 3rd, Cohen A, Doroshow J, Kiel K, Niederhuber J, et al. NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10(11 suppl): 140-75.
29. Ettinger DS, Cox JD, Ginsberg RJ, Komaki R, Kris MG, Livingston RB, et al. NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10(11 suppl):81-111.
30. Forastiere A, Goepfert H, Goffinet D, Hong KW, Laramore G, Mittal B, et al. NCCN Practice Guidelines for Head and Neck Cancer. Oncology (Huntingt) 1998;12:39-147.
31. Ozols RF. Update of the NCCN ovarian cancer practice guidelines. Oncology (Huntingt) 1997;11:95-105.
32. Shipp MA, Horning SJ, Ambinder RF, Pezner RD, Appelbaum FR, Rodriguez MA. et al. NCCN preliminary non-Hodgkin's lymphoma practice guidelines. Oncology (Huntingt) 1997;11:281-346.
33. Okamoto H, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, et al. Chemotherapy-induced anemia in patients with primary lung cancer. Ann Oncol 1992;3:819-24.
34. Greco FA, Hainsworth JD. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial. Semin Oncol 1997;24(suppl 12):S12-14-S12-17.
35. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996;14:2054-60.
36. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-70.
37. Ranson MR, Jayson G, Perkins S, Anderson H, Thatcher N. Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule. Semin Oncol 1997;24(suppl 12):S12-6-S12-9.
38. Millward MJ, Bishop JF, Friedlander M, Levi JA, Goldstein D, Olver IN, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1996;14:142-8.
39. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-8.
40. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995;75:968-72.
41. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994;12:1232-7.
42. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994;12:1238-44.
43. Anderson H, Lund B, Bach F, Thatcher N, Walling J. Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1821-6.
44. Stadler WM, Kuzel T, Roth B, Raghaven D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:3394-8.
45. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996; 32A:243-8.
46. O'Rourke M, Crawford J, Schiller J, Laufman L, Yanovich S, Ozer H, et al. Survival advantage for patients with stage IV NSCLC treated with single agent Navelbine® in a randomized controlled trial [abstract]. Proc ASCO 1993;12:343.
47. nd ed. Montvale (NJ): Medical Economics Co.; 1998. p. 1162-5.
48. Vokes EE, Rosenberg RK, Jahanzeb M, Craig JB, Gralla RJ, Belani CP, et al. Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. J Clin Oncol 1995;13:637-44.
49. 2) plus carboplatin in non-small cell lung cancer: a randomized study. Semin Oncol 1997;24(suppl 12):S12-30-S12-33.
50. Pirker R, Krajnik G., Zochbauer S, Malayeri R, Kneussl M, Huber H. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 1995;6:833-5.
51. Von Pawel J, Wagner H, Niederle N, Heider A, Koschel G, Gromotka E, et al. Paclitaxel and cisplatin in patients with non-small cell lung cancer: results of a phase II trial. Semin Oncol 1996;23:7-9.
52. Postmus PE, Giaccone G, Debruyne C, Sahmoud T, Splinter TA, van Zandwijk N. Results of the phase II EORTC study comparing paclitaxel/ cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group. Semin Oncol 1996;23(suppl 12):10-3.
53. Miller AA, Niell HB, Griffin JP. Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer. Lung Cancer 1995;12:59-65.
54. Robert F, Wheeler RH, Molthrop D, Bailey A, Chen S, Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer. Am J Clin Oncol 1994; 17:383-6.
55. Shepherd FA, Cormier Y, Burkes R, Evans WK, Goss G, Klimo P, et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 1997;24(suppl 8):S8-27-S8-30.
56. Abratt RP, Hacking DJ, Goedhals L, Bezwoda WR. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma. Semin Oncol 1997:24(suppl 8):S8-18-S8-23.
57. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16:2459-65.
58. Ellis PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE, et al. Symptom relief with MVP (mitomycin C. vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995;71: 366-70.
59. Kosty MP, Fleishman SB, Hemdon JE 2nd, Coughlin K, Kornblith AB, Scalzo A, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994;12:1113-20.
60. Ihde DC, Pass HI, Glatstein E. Small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Vol 1. 5th ed. Philadelphia (PA): Lippincott-Raven Publishers; 1997. p. 911-49.
61. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995;13: 1430-5.
62. Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1996;14:2345-52.
63. Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 1994;30A: 1058-60.
64. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe CH, van Glabbeke M, Noseda MA, Ardizzoni A, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993:29A:1720-2.
65. Furuse K, Kubota K, Kawahara M, Ogawara M, Kinuwaki E, Motomiya M, et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small-cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Lung Cancer 1994;11: 385-91.
66. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15: 2090-6.
67. Hainsworth JD, Levitan N, Wampler GL, Belani CP, Seyedsadr MS, Randolf J, et al. Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. J Clin Oncol 1995;13:1436-42.
68. Loehrer PJ Sr, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995; 13:2594-9.
69. Miller AA, Herndon JE 2nd, Hollis DR, Ellerton J, Langleben A, Richards F 2nd. et al. Schedule dependency of 21-day oral versus 3-day intravenous eloposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995;13:1871-9.
70. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5:601-7.
71. Luikart SD, Goutsou M, Mitchell ED, Van Echo DA, Modeas CR, Propert KJ, et al. Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B. Am J Clin Oncol 1993;16:127-31.
72. Figueredo AT, Hryniuk WM, Strautmanis I, Frank G, Rendell S. Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985;3:54-64.
73. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, et al. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1995;13:1615-22.
74. Faylona EA, Loehrer PJ, Ansari R, Sandler AB, Gonin R, Einhorn LH. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. J Clin Oncol 1995;13:1209-14.
75. Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 1997;15:3464-70.
76. Davidson NG. Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semin Oncol 1996;23(suppl 11): 6-10.
77. Chevallier B, Fumoleau P, Kerbrat P, Dieres V, Roche H, Krakowski I, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995;13:314-22.
78. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:58-65.
79. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722-30.
80. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11: 1245-52.
81. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14:1858-67.
82. Dieras V, Maryy M, Tubiana N, Corette L, Morvan F, Serin D, et al. Phase 11 randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 1995;22(suppl 8):33-9.
83. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995;13:1152-9.
84. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-94.
85. Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-85.
86. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994;12:2094-101.
87. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Homer D, et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5:423-6.
88. Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-retractory advanced breast cancer. J Clin Oncol 1995;13:2567-74.
89. Budd GT, Green S, O'Bryan RM, Martino S, Abeloff MD, Rinehart JJ, et al. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an Intergroup study. J Clin Oncol 1995;13:831-9.
90. Bezwoda WR, Seymour L, Dansey RD, High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-9.
91. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-99.
92. Aisner J, Cirrincione C, Perloff M, Perry M, Budman D, Abrams J, et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast - a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. J Clin Oncol 1995;13:1443-52.
93. Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996;7:687-93.
94. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT Jr, Hellman S. Rosenberg SA, editors. Cancer: principles and practice of oncology. Vol 2. 5th ed. Philadelphia (PA): Lippincott-Raven Publishers; 1997. p. 1502-34.
95. Jones A, Wiltshaw E, Harper P, Slevin M, Shepherd J, Mansi J, et al. A randomized study of high vs conventional-dose carboplatin for previously untreated ovarian cancer [abstract]. Br J Cancer 1992;65(suppl 16): 15.
96. Rozencweig M, Martin A, Beltangady M, Bragman K, Goodlow J, Wiltshaw E, et al. Randomized trials of carboplatin versus cisplatin in advanced ovarian cancer. In: Bunn PA, Canetta R, Ozols RF, Rozencweig M, editors. Carboplatin: current perspectives and future directions. Philadelphia (PA): Saunders; 1990. p. 175-86.
97. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
98. nd ed. Montvale (NJ): Medical Economics Co.; 1998. p. 762-6.
99. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-53.
100. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.
101. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL, Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992;10:1748-53.
102. Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994;86:18-24.
103. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-61.
104. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14:1552-7.
105. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M. et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-8.
106. Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837-42.
107. Piccart MJ, Gore M, Ten Bokkel Huinink W, Van Oosterom A, Verweij, Wanders J, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995;87:676-81.
108. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994;12:60-3.
109. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405-10.
110. Dorval T, Soussain C, Beuzeboc P, Garcia-Giralt E, Jouve M, Livartowski A, et al. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. J Infus Chemother 1996;6:47-9.
111. Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989;7:1672-6.
112. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
113. Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, et al. Paclitaxel with carhoplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Semin Oncol 1997;24(suppl 15):S15-57-S15-61.
114. Coeffic D, Benhammouda A, Antoine EC, Rixe O, Paraiso D, Auclerc G. et al. Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma. Semin Oncol 1997;24(suppl 2):S2-38-S2-40.
115. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer [published erratum appears in J Clin Oncol 1992; 10:15051. J Clin Oncol 1992;10:706-17.
116. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, et al. Cisplatin-cyclophosphamide versus carhoplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992; 10: 718-26.
117. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995;13:1589-99.
118. Alberts DS, Liu PY, Hannigan EV, OToole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
119. Conte PF, Bruzzone M, Chiara S, Sertoli MR, Daga MG, Rubagotti A, et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer (published erratum appears in J Clin Oncol 1986;4:1284]. J Clin Oncol 1986;4:965-71.
120. Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, et al. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1994;12:1366-74.
121. Meyer RM, Browman GP, Samosh ML, Benger AM, Bryant-Lukosius D, Wilson WE, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995;13:2386-93.
122. Gordon LI, Harrington D, Andersen J, Colgan J, Click J, Neiman R, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342-9.
123. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327: 1478-84.
124. Canellos GP, Petroni GR, Barcos M, Duggan DB, Peterson BA. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. J Clin Oncol 1995;13:2005-11.
125. Hill M, Norman A, Cunningham D, Findlay M, Watson M, Nicolson V, et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 1995;13:2317-23.
126. Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group [published erratum appears in J Clin Oncol 1990;8:185]. J Clin Oncol 1989;7;1419-26.
127. Greco FA, Figlin R, York M, Einhorn L, Schilsky R, Marshall EM, et al. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 1996;14:2674-81.
128. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-60.
129. Creemers GJ, Gerrits CJ, Schellens JH, Planting AS, van der Burg ME, van Beurden VM, et al. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996;14:2540-5.
130. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-35.
131. Corfu-A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995;13:921-8.
132. Kosmidis PA, Tsavaris N, Skarlos D, Theocharis D, Samantas E, Pavlidis N, et al. Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol 1996;14:2682-7.
133. Gonzalez Baron M, Feliu J, Garcia Giron C, Espinosa J, Martinez B, Blanco E, et al. UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. Oncology 1997;54 Suppl 1:24-9.
134. Sanchiz F, Milla A. Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer. Jpn J Clin Oncol 1994;24:322-6.
135. Schantz SP, Harrison LB, Forastiere AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, oropharynx. In: DeVita VT Jr, Hellman S. Rosenberg SA, editors. Cancer: principles and practice of oncology. Vol 1. 5th ed. Philadelphia (PA): Lippincott-Raven Publishers; 1997. p. 741-801.
136. Forastiere AA, Neuberg D, Taylor SG 4th, DeConti R, Adams G. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group trial. J Natl Cancer Inst Monogr 1993;115:181-4.
137. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:533-7.
138. Smith RE, Lew D, Rodriguez GI, Taylor SA, Schuller D, Ensley JF. Evaluation of topotecan in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study. Invest New Drugs 1996;14:403-7.
139. Jacobs C, Lyman G, Velez-Garcia E, Srihhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63.
140. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51.
141. Paredes J, Hong WK, Felder TB, Dimery IW, Choksi AJ, Newman RA, et al. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/ or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 1988;6:955-62.
142. Hussain M, Salwen W, Kucuk O, Ensley J. Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report. Semin Oncol 1997;24(suppl 19):S19-43-S19-45.
143. Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:1325-30.
144. Fountzilas G, Skarlos D, Athanassiades A, Kulogera-Fountzila A, Samantas E, Bacoyiannis C, et al. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1997;8:451-5.
145. Koeller JM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 1998;18:156-69.
146. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP, Transfusion medicine. First of two parts - blood transfusion. N Engl J Med 1999;340:438-47.
147. Dodd RY. Adverse consequences of blood transfusion: quantitative risk estimates. In: Nance ST, editor. Blood supply: risks perceptions and prospects
148. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90.
149. Lackritz EM, Satten GA, Aberle-Grasse J, Dod RY, Raimondi VP, Janssen RS, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333: 1721-5.
150. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990;30:583-90.
151. Linden JV, Paul B, Dresslier KP. A report of 104 transfusion errors in New York State. Transfusion 1992;32:601-6.
152. Ness PM, Shirey RS, Thoman SK, Buck SA. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion 1990;30:688-93.
153. Shulman IA. The risk of an overt hemolytic transfusion reaction following the use of an immediate spin crossmatch. Arch Pathol Lab Med 1990; 114:412-4.
154. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25:573-7.
155. Rieger PT, Haeuber D. A new approach to managing chemotherapy-related anemia: nursing implications of epoetin alfa. Oncol Nurs Forum 1995;22:71-81.
156. Surgenor DM, Wallace EL, Hao SH, Chapman RH. Collection and transfusion of blood in the United States, 1982-1988. N Engl J Med 1990; 322:1646-51.
157. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993;29A Suppl 2:S2-8.
158. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-62.
159. Crawford J, Blackwell S, Shoemaker D, Pupa MR, Mulhausen T, Herndon J, et al. Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-CSF support [abstract]. Lung Cancer 1997;18(suppl 1):205.
160. Dunphy FR, Dunleavy TL, Harrison BR, Boyd JH, Varvares MA, Dunphy CH, et al. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 1997;79:1623-8.
161. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;315:164-70.